Tags

Type your tag names separated by a space and hit enter

The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients.
Biol Trace Elem Res 1997; 56(3):331-41BT

Abstract

The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 4000 micrograms per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4 +/- 22.86 to 157.04 +/- 60.23 ng/mL (P < 0.001) in patients received Se. The cisplatin dosage was iv administration in 60-80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35 +/- 2.01 vs 2.31 +/- 1.38 [x10(9)L])/L, p < 0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1 +/- 82.2 vs 723.6 +/- 192.6 IU, p < 0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62 +/- 38 mL, p < 0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72 h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin.

Authors+Show Affiliations

Department of Medical Oncology, Beijing Hospital, P.R., China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

9197929

Citation

Hu, Y J., et al. "The Protective Role of Selenium On the Toxicity of Cisplatin-contained Chemotherapy Regimen in Cancer Patients." Biological Trace Element Research, vol. 56, no. 3, 1997, pp. 331-41.
Hu YJ, Chen Y, Zhang YQ, et al. The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biol Trace Elem Res. 1997;56(3):331-41.
Hu, Y. J., Chen, Y., Zhang, Y. Q., Zhou, M. Z., Song, X. M., Zhang, B. Z., ... Cheng, G. (1997). The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. Biological Trace Element Research, 56(3), pp. 331-41.
Hu YJ, et al. The Protective Role of Selenium On the Toxicity of Cisplatin-contained Chemotherapy Regimen in Cancer Patients. Biol Trace Elem Res. 1997;56(3):331-41. PubMed PMID: 9197929.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The protective role of selenium on the toxicity of cisplatin-contained chemotherapy regimen in cancer patients. AU - Hu,Y J, AU - Chen,Y, AU - Zhang,Y Q, AU - Zhou,M Z, AU - Song,X M, AU - Zhang,B Z, AU - Luo,L, AU - Xu,P M, AU - Zhao,Y N, AU - Zhao,Y B, AU - Cheng,G, PY - 1997/3/1/pubmed PY - 1997/3/1/medline PY - 1997/3/1/entrez SP - 331 EP - 41 JF - Biological trace element research JO - Biol Trace Elem Res VL - 56 IS - 3 N2 - The effect of selenium (Se) in reducing the toxicity of cisplatin in cancer patients was studied. Forty-one patients were randomized into group A (20 patients with Se administration in first cycle of chemotherapy as study cases and without Se in second cycle of chemotherapy as control) and group B (21 patients without Se in first cycle of chemotherapy and with Se in second cycle of chemotherapy). The 4000 micrograms per day of Se as Seleno-Kappacarrageenan were administered from 4 before to 4 d after chemotherapy for study cases. The serum Se increased from 70.4 +/- 22.86 to 157.04 +/- 60.23 ng/mL (P < 0.001) in patients received Se. The cisplatin dosage was iv administration in 60-80 mg/m2 on the first day. The results showed that the peripheral WBC counts on day 14 after initiation of chemotherapy in study cases was significantly higher than the controls (3.35 +/- 2.01 vs 2.31 +/- 1.38 [x10(9)L])/L, p < 0.05). On the other hand, the consumption of GCSF for the cases was significantly less than the controls (110.1 +/- 82.2 vs 723.6 +/- 192.6 IU, p < 0.05). The volumes of blood transfusion for the study group were also significantly less than the controls (0 vs 62 +/- 38 mL, p < 0.05). The nephrotoxicity of cisplatin was measured by urine enzymes (NAG, GGT, AAP, LAP, and ALP) were determined prior to and at 2, 24, 48, and 72 h after initiation of chemotherapy. The urine enzymes NAG, GGT, AAP, and ALP after chemotherapy for cases were significantly lower than the controls. No toxicity of Seleno-Kappacarrageenan was noted. The above results suggest that the Se can be used as an agent for reducing the nephrotoxicity and bone marrow suppression induced by cisplatin. SN - 0163-4984 UR - https://www.unboundmedicine.com/medline/citation/9197929/full_citation L2 - https://dx.doi.org/10.1007/BF02785304 DB - PRIME DP - Unbound Medicine ER -